Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
GH Research PLC
GHRS
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.8B
$26.88
▲ +1.75%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$11.32 - $28.96
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 75.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary 5-MeO-DMT formulations with novel delivery mechanisms
- Advanced clinical development stage with completed Phase 1/2 trials
- First-mover advantage in psychedelic-assisted medicine for TRD
- Diversified product pipeline addressing multiple neuropsychiatric indications
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Advancement of GH001 through Phase 2/3 clinical trials toward FDA approval
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+81.3% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GHRS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 7, 2026
MAY 14, 2026
Reported EPS of -$0.31 vs -$0.27 consensus (-14.8% surprise).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-14.8%
Next: May 7, 2026
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$50.00
▲ +86.0% vs $26.88
Latest: HC Wainwright · $65.00 · May 19, 2026
2 analysts covering